Influenza Diagnostics Market

Influenza Diagnostics Market by Test type (Molecular (RT-PCR,LAMP, NASBA), Traditional (Viral Culture, Direct Fluorescent Antibody, Rapid Influenza Detection Tests, Serological Assays)), End user (Hospital, Clinical Laboratories) - Global Forecast to 2025

Report Code: MD 7514 Apr, 2020, by marketsandmarkets.com
COVID-19

Get in-depth analysis of the COVID-19 impact on the Influenza Diagnostics Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the Influenza Diagnostics Market

Request For Special Pricing

[127 Pages Report] The global influenza diagnostic market is projected to reach USD 1,012 million in 2025 from USD 695 million in 2020, at a CAGR of 7.8% during the forecast period. Market growth is largely driven by factors such as the increasing prevalence of influenza, growth in research funding for influenza diagnostics, and the rising demand for faster diagnosis are the major factors that are expected to drive the growth of this market in the coming years. However, variability in sensitivity and specificity among influenza diagnostic tests, the presence of a complex regulatory framework for the approval of new diagnostic tests, and rising healthcare costs are expected to restrain the growth of this market to a certain extent in the coming years.

Attractive Opportunities in influenza diagnostics market

By test type, the RIDT segment accounted for the largest share for traditional diagnostic tests of the influenza diagnostic market.

The RIDT segment accounted for the largest share of the influenza diagnostics market for traditional diagnostic tests of the influenza diagnostic market in 2019. The large share of this segment can be attributed to increased adoption of cost-effective and faster RIDT as a first line of diagnosis and screening process have been raised among the end-users. This is a major factor responsible for the largest share of the RIDT market.

By end-user, the hospital's segment accounted for the largest share of the market.

The hospital's segment accounted for the largest share of the influenza diagnostic market in 2019, influenza disease diagnostics is commonly carried out in hospitals, as it is complex in nature and requires technologically advanced product, this is the major factor driving the growth of this segment.

Attractive Opportunities in influenza diagnostics market

North America accounted for the largest share of the market.

The influenza diagnostic market is divided into four major regions-North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share of the global influenza diagnostic market, closely followed by Europe. Factors such as the increasing prevalence of influenza and increasing number of influenza screening test performed in this region are driving the growth of the North American market during the forecast period.

Key Market Players

The major companies in the influenza diagnostic market include Hoffmann-La Roche AG (Switzerland), Quidel Corporation (US), Thermo Fisher Scientific Inc. (US), Abbott Laboratories, Inc. (US), and Hologic Inc. (US).

Hoffmann-La Roche AG (Switzerland) dominated the global influenza diagnostics market in 2019. The company operates in the influenza diagnostics market by providing molecular diagnostic kits for the detection of various strains of infection-causing agents. The company’s strategic initiatives, such as obtaining CLIA waiver approvals for its influenza assays and test kits, will help it in establishing its presence in various international markets. Also, its strong distribution network and geographic presence will result in growth opportunities for the company during the forecast period.

Scope of the Report

Report Metric

Details

Market Size Available for Years

2018–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Units

Values (USD Million)

Segments Covered

By Test Type, End-User, and Region

Geographies Covered

North America (US, Canada), Europe (France, UK, RoE), APAC (China, Japan, India, RoAPAC), and RoW

Top Companies Covered

F. Hoffmann-La Roche AG (Switzerland), Quidel Corporation (US), Thermo Fisher Scientific (US), Abbott Laboratories (US), Hologic (US), Becton, Dickinson, and Company (US), DiaSorin S.p.A (Italy), Luminex Corporation (US), Meridian Bioscience (US), GenMark Diagnostics (US), SA Scientific (US), Sekisui Diagnostics (US), bioMιrieux SA (France), Danaher Corporation (US), Siemens Healthineers (Germany), Tecan Trading AG (Switzerland), and ELITech (France), Mast Group (England), altona Diagnostics (Germany), Coris BioConcept (Belgium), Genome Diagnostics (India), Germaine Laboratories (US), Response Biomedical (Canada), TAUNS Laboratories (Japan), and TRUPCR (India)

Based on test type, the influenza diagnostic market is segmented as follows:

  • Traditional Diagnostic Tests
    • RIDT
    • Viral Culture
    • DFA
    • Serological assays
  • Molecular Diagnostic Tests
    • RT-PCR
    • INNAT
      • TMA
      • LAMP
      • NASBA
      • Other INNAT
    • Other Molecular Tests

Based on end-user, the influenza diagnostic market is segmented as follows:

  • Hospitals
  • Clinical Laboratories
  • Other End-User

Based on the region, the influenza diagnostic market is segmented as follows:

  • North America
    • US
    • Canada
  • Europe
    • France
    • UK
    • RoE
  • Asia Pacific
    • China
    • Japan
    • India
    • RoAPAC
  • RoW

Recent Developments:

  • In 2018, Siemens Healthineers acquired Fast Track Diagnostics Ltd., a manufacturer of a broad range of CE-marked infectious disease detection tests and syndromic panels. Through this acquisition, Siemens Healthineers expanded its molecular diagnostics portfolio for infectious diseases.
  • In 2018, Quidel Corporation (US) got approval for QuickVue Influenza A+B Test product.
  • In 2018,Abbott Laboratories (US) got approval for ID NOW Influenza A & B 2 Assay product
  • In 2017, Becton Dickinson, and Company got approval for BD Veritor System Flu A+B product.

Key questions addressed by the report:

  • Who are the major players in the influenza diagnostics market?
  • What are the regional growth trends and the largest revenue-generating regions in the influenza diagnostic market?
  • What are the major drivers and challenges in the influenza diagnostics market?
  • What are the major product segments in the influenza diagnostics market?
  • What are the major end-users in the influenza diagnostics market?

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 15)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 18)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
           2.1.3 DATA TRIANGULATION
    2.2 MARKET ESTIMATION METHODOLOGY
    2.3 MARKET GROWTH RATE PROJECTIONS
    2.4 RESEARCH ASSUMPTIONS

3 EXECUTIVE SUMMARY (Page No. - 24)

4 PREMIUM INSIGHTS (Page No. - 26)
    4.1 INFLUENZA DIAGNOSTICS MARKET OVERVIEW
    4.2 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE & COUNTRY (2019)
    4.3 INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER (2019)

5 MARKET OVERVIEW (Page No. - 28)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           5.2.1 DRIVERS
                    5.2.1.1 Increasing prevalence of influenza
                    5.2.1.2 Growth in influenza research
                    5.2.1.3 Rising demand for rapid disease diagnosis
           5.2.2 RESTRAINTS
                    5.2.2.1 Variability in test sensitivity and specificity
                    5.2.2.2 Stringent regulatory framework
                    5.2.2.3 Rising healthcare costs
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Advancements in genomic and proteomic technologies
                    5.2.3.2 Significant growth prospects in developing countries
           5.2.4 CHALLENGES
                    5.2.4.1 Lack of skilled professionals
    5.3 THE IMPACT OF COVID-19 OUTBREAK ON THE GROWTH OF INFLUENZA DIAGNOSTICS MARKET
           5.3.1 SIMILARITIES IN INFLUENZA AND COVID-19 SYMPTOMS
           5.3.2 WHO RECOMMENDATIONS FOR THE CO-TESTING OF COVID-19 AND OTHER RESPIRATORY PATHOGENS, INCLUDING INFLUENZA AND RSV
           5.3.3 INCREASED ADOPTION OF THE INFLUENZA VACCINE (FLU SHOT) IN THE HEALTHCARE SYSTEM
           5.3.4 INCREASING FOCUS OF DIAGNOSTIC MANUFACTURERS ON THE DEVELOPMENT OF NEW COVID-19 TESTS

6 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE (Page No. - 34)
    6.1 INTRODUCTION
    6.2 TRADITIONAL DIAGNOSTIC TESTS
           6.2.1 RIDT
                    6.2.1.1 RIDT tests are widely used owing to their ease of use and rapid interpretability of results
           6.2.2 VIRAL CULTURE
                    6.2.2.1 Wide use of viral culture as a confirmatory test to ensure the results of RIDT to drive market growth
           6.2.3 DFA
                    6.2.3.1 Adoption of DFA tests is increasing due to their higher sensitivity as compared to RIDT
           6.2.4 SEROLOGICAL ASSAYS
                    6.2.4.1 Development of lab-on-chip-based multiplex assays to support market growth
    6.3 MOLECULAR DIAGNOSTIC TESTS
           6.3.1 RT-PCR
                    6.3.1.1 Ability of RT-PCR to distinguish between influenza A and B viruses driving its adoption in clinical settings
           6.3.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS
                    6.3.2.1 TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS
                               6.3.2.1.1 TMA accounts for the largest share of the INAAT market
                    6.3.2.2 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS
                               6.3.2.2.1 Rapidity, stability, and sensitivity have driven the use of LAMP
                    6.3.2.3 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION TESTS
                               6.3.2.3.1 NASBA is highly preferred in hospital and clinical settings as it reduces the need for additional reverse transcription steps
                    6.3.2.4 OTHER INAAT TESTS
           6.3.3 OTHER MOLECULAR TESTS

7 INFLUENZA DIAGNOSTICS MARKET, BY END USER (Page No. - 52)
    7.1 INTRODUCTION
    7.2 HOSPITALS
           7.2.1 HOSPITALS ACCOUNTED FOR THE LARGEST SHARE OF THE MARKET IN 2019
    7.3 CLINICAL LABORATORIES
           7.3.1 ADVANTAGES OFFERED BY CLINICAL LABORATORIES IN TERMS OF SERVICE COSTS AND TURNAROUND TIME TO SUPPORT MARKET GROWTH
    7.4 OTHER END USERS

8 INFLUENZA DIAGNOSTICS MARKET, BY REGION (Page No. - 58)
    8.1 INTRODUCTION
    8.2 NORTH AMERICA
           8.2.1 US
                    8.2.1.1 The US dominated the North American market in 2019
           8.2.2 CANADA
                    8.2.2.1 Government initiatives and technological advancements in diagnostic techniques to support market growth
    8.3 EUROPE
           8.3.1 FRANCE
                    8.3.1.1 Supportive government policies drive market growth in France
           8.3.2 UK
                    8.3.2.1 Frequent influenza outbreaks in the UK to boost the growth of the influenza diagnostics market
           8.3.3 ROE
    8.4 ASIA PACIFIC
           8.4.1 INCREASING HEALTHCARE EXPENDITURE AND RISING AWARENESS INDICATE FAVORABLE PROSPECTS FOR MARKET GROWTH
    8.5 REST OF THE WORLD

9 COMPETITIVE LANDSCAPE (Page No. - 82)
    9.1 INTRODUCTION
    9.2 MARKET RANKING ANALYSIS, 2019
    9.3 COMPETITIVE LEADERSHIP MAPPING
           9.3.1 VISIONARY LEADERS
           9.3.2 INNOVATORS
           9.3.3 DYNAMIC DIFFERENTIATORS
           9.3.4 EMERGING COMPANIES
    9.4 COMPETITIVE SCENARIO
           9.4.1 KEY PRODUCT APPROVALS
           9.4.2 KEY ACQUISITIONS

10 COMPANY PROFILES (Page No. - 86)
     10.1 F. HOFFMANN-LA ROCHE AG
             10.1.1 BUSINESS OVERVIEW
             10.1.2 PRODUCTS OFFERED
             10.1.3 MNM VIEW
     10.2 QUIDEL CORPORATION
             10.2.1 BUSINESS OVERVIEW
             10.2.2 PRODUCTS OFFERED
             10.2.3 RECENT DEVELOPMENTS
             10.2.4 MNM VIEW
     10.3 THERMO FISHER SCIENTIFIC, INC.
             10.3.1 BUSINESS OVERVIEW
             10.3.2 PRODUCTS OFFERED
             10.3.3 MNM VIEW
     10.4 ABBOTT LABORATORIES, INC.
             10.4.1 BUSINESS OVERVIEW
             10.4.2 PRODUCTS OFFERED
             10.4.3 RECENT DEVELOPMENTS
     10.5 HOLOGIC, INC.
             10.5.1 BUSINESS OVERVIEW
             10.5.2 PRODUCTS OFFERED
             10.5.3 RECENT DEVELOPMENTS
     10.6 BECTON, DICKINSON AND COMPANY
             10.6.1 BUSINESS OVERVIEW
             10.6.2 PRODUCTS OFFERED
             10.6.3 RECENT DEVELOPMENTS
     10.7 DANAHER CORPORATION
             10.7.1 BUSINESS OVERVIEW
             10.7.2 PRODUCTS OFFERED
             10.7.3 RECENT DEVELOPMENTS
     10.8 DIASORIN SA
             10.8.1 BUSINESS OVERVIEW
             10.8.2 PRODUCTS OFFERED
     10.9 MERIDIAN BIOSCIENCE
             10.9.1 BUSINESS OVERVIEW
             10.9.2 PRODUCTS OFFERED
             10.9.3 RECENT DEVELOPMENTS
     10.1 LUMINEX CORPORATION
             10.10.1 BUSINESS OVERVIEW
             10.10.2 PRODUCTS OFFERED
     10.11 BIOMΙRIEUX SA
             10.11.1 BUSINESS OVERVIEW
             10.11.2 PRODUCTS OFFERED
             10.11.3 RECENT DEVELOPMENTS
     10.12 GENMARK DIAGNOSTICS, INC.
             10.12.1 BUSINESS OVERVIEW
             10.12.2 PRODUCTS OFFERED
             10.12.3 RECENT DEVELOPMENTS
     10.13 SIEMENS HEALTHINEERS
             10.13.1 BUSINESS OVERVIEW
             10.13.2 PRODUCTS OFFERED
             10.13.3 RECENT DEVELOPMENTS
     10.14 TECAN TRADING
             10.14.1 BUSINESS OVERVIEW
             10.14.2 PRODUCTS OFFERED
     10.15 SEKISUI DIAGNOSTICS
             10.15.1 BUSINESS OVERVIEW
             10.15.2 PRODUCTS OFFERED
     10.16 SA SCIENTIFIC, LTD.
             10.16.1 BUSINESS OVERVIEW
             10.16.2 PRODUCTS OFFERED
     10.17 ALTONA DIAGNOSTICS GMBH
             10.17.1 BUSINESS OVERVIEW
             10.17.2 PRODUCTS OFFERED
     10.18 CORIS BIOCONCEPT SPRL
             10.18.1 BUSINESS OVERVIEW
             10.18.2 PRODUCTS OFFERED
     10.19 ELITECH GROUP
             10.19.1 BUSINESS OVERVIEW
             10.19.2 PRODUCTS OFFERED
     10.20 MAST GROUP LTD.
             10.20.1 BUSINESS OVERVIEW
             10.20.2 PRODUCTS OFFERED
     10.21 RIGHT-TO-WIN

11 APPENDIX (Page No. - 121)
     11.1 DISCUSSION GUIDE
     11.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     11.3 AVAILABLE CUSTOMIZATIONS
     11.4 RELATED REPORTS
     11.5 AUTHOR DETAILS


LIST OF TABLES (102 Tables)

TABLE 1 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 2 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 3 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 4 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 5 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 6 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 7 RIDT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 8 NORTH AMERICA: RIDT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 9 EUROPE: RIDT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 10 VIRAL CULTURE MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 11 NORTH AMERICA: VIRAL CULTURE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 12 EUROPE: VIRAL CULTURE MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 13 DFA MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 14 NORTH AMERICA: DFA MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 15 EUROPE: DFA MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 16 SEROLOGICAL ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 17 NORTH AMERICA: SEROLOGICAL ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 18 EUROPE: SEROLOGICAL ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 19 MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 20 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 21 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 22 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 23 MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 24 RT-PCR MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 25 NORTH AMERICA: RT-PCR MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 26 EUROPE: RT-PCR MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 27 INAAT MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 28 NORTH AMERICA: INAAT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 29 EUROPE: INAAT MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 30 INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 31 TMA ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 32 NORTH AMERICA: TMA ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 33 LAMP ASSAYS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 34 NORTH AMERICA: LAMP ASSAYS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 35 NASBA TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 36 NORTH AMERICA: NASBA TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 37 OTHER INAAT TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 38 NORTH AMERICA: OTHER INAAT TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 39 OTHER MOLECULAR TESTS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 40 NORTH AMERICA: OTHER MOLECULAR TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 41 EUROPE: OTHER MOLECULAR TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 42 INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 43 INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2018–2025 (USD MILLION)
TABLE 44 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 45 EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 46 INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY REGION, 2018–2025 (USD MILLION)
TABLE 47 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 48 EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 49 INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
TABLE 50 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 51 EUROPE: INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 52 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2018–2025 (USD MILLION)
TABLE 53 INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 54 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 55 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 56 NORTH AMERICA: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 57 NORTH AMERICA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 58 NORTH AMERICA: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 59 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 60 US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 61 US: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 62 US: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 63 US: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 64 US: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 65 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 66 CANADA: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 67 CANADA: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 68 CANADA: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 69 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 70 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
TABLE 71 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 72 EUROPE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 73 EUROPE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 74 EUROPE: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 75 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 76 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 77 FRANCE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 78 FRANCE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 79 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 80 UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 81 UK: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 82 UK: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 83 UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 84 ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 85 ROE: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 86 ROE: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 87 ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 88 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 89 ASIA PACIFIC: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 90 ASIA PACIFIC: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 91 ASIA PACIFIC: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 92 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)
TABLE 93 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY/REGION, 2018–2025 (USD MILLION)
TABLE 94 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 95 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 96 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 97 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 98 ROW: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
TABLE 99 ROW: TRADITIONAL DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 100 ROW: MOLECULAR DIAGNOSTICS MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 101 ROW: INAAT MARKET, BY TYPE, 2018–2025 (USD MILLION)
TABLE 102 ROW: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION)


LIST OF FIGURES (34 Figures)

FIGURE 1 BREAKDOWN OF PRIMARIES: INFLUENZA DIAGNOSTICS MARKET
FIGURE 2 DATA TRIANGULATION METHODOLOGY
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE-BASED ESTIMATION)
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 2 (TEST TYPE-BASED ESTIMATION)
FIGURE 5 INFLUENZA DIAGNOSTICS MARKET: CAGR PROJECTIONS
FIGURE 6 INFLUENZA DIAGNOSTICS MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS, OPPORTUNITIES, RESTRAINTS, & CHALLENGES
FIGURE 7 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019
FIGURE 8 INFLUENZA DIAGNOSTIC MARKET, BY END USER, 2019 VS. 2025
FIGURE 9 GEOGRAPHICAL SNAPSHOT OF THE INFLUENZA DIAGNOSTIC MARKET
FIGURE 10 INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET GROWTH
FIGURE 11 TRADITIONAL DIAGNOSTIC TESTS TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICAN INFLUENZA DIAGNOSTIC MARKET IN 2019
FIGURE 12 HOSPITALS DOMINATED THE INFLUENZA DIAGNOSTICS MARKET IN 2019
FIGURE 13 INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE INFLUENZA DIAGNOSTICS MARKET
FIGURE 15 INFLUENZA DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2019)
FIGURE 16 PERCENTAGE SHARE OF INFLUENZA SPECIMEN TESTED, BY REGION (2019)
FIGURE 17 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT, 2019
FIGURE 18 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT
FIGURE 19 RANK OF COMPANIES IN THE INFLUENZA DIAGNOSTICS MARKET, 2019
FIGURE 20 INFLUENZA DIAGNOSTICS MARKET (GLOBAL) GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2019
FIGURE 21 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT
FIGURE 22 QUIDEL CORPORATION: COMPANY SNAPSHOT
FIGURE 23 COMPANY SNAPSHOT: THERMO FISHER SCIENTIFIC, INC.
FIGURE 24 COMPANY SNAPSHOT: ABBOTT LABORATORIES, INC.
FIGURE 25 HOLOGIC, INC.: COMPANY SNAPSHOT
FIGURE 26 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT
FIGURE 27 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 28 DIASORIN SA: COMPANY SNAPSHOT
FIGURE 29 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT
FIGURE 30 LUMINEX CORPORATION: COMPANY SNAPSHOT
FIGURE 31 BIOMΙRIEUX SA: COMPANY SNAPSHOT
FIGURE 32 GENMARK DIAGNOSTICS, INC.: COMPANY SNAPSHOT
FIGURE 33 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT
FIGURE 34 TECAN TRADING: COMPANY SNAPSHOT

The study involved two major activities in estimating the current size of the influenza diagnostics market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing estimates with industry experts across the value chain through primary research. Both revenue-based and product-based estimation approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.

Secondary Research

The secondary sources referred to for this research study include publications from government sources, such as World Health Organization (WHO), US Food and Drug Administration (FDA), European Centre for Disease Prevention and Control (ECDC), National Center for Biotechnology Information, National Institutes of Health (NIH), Organisation for Economic Co-operation and Development (OECD), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), American Journal of Infectious Diseases, National Center for Biotechnology Information (NCBI) and others. Secondary sources also include corporate & regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines & research journals; press releases; and trade, business, and professional associations, among others. Secondary data was collected and analyzed to arrive at the overall size of the global influenza diagnostics market, which was validated through primary research.

Primary Research

The influenza diagnostic market comprises several stakeholders such as kits, assay manufacturing companies, vendors and distributors of influenza diagnostic kits and assays, market research and consulting firms, healthcare service providers, CROs, and government bodies, and municipal corporations. Several primary interviews were conducted with market experts from both the demand side (such as personnel from hospitals, research personnel from clinical laboratories, academic and research institutes, purchase managers in healthcare provider organizations) and supply-side (such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners, among others) across four major regions—North America, Europe, Asia Pacific, and the Rest of the World. Approximately 70% and 30% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

Attractive Opportunities in influenza diagnostics market

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

For calculating the global market value, segmental revenues were arrived at based on the revenue mapping of major players active in the influenza diagnostic market. This process involved the following steps:

  • Generating a list of the major global players operating in the influenza diagnostic market
  • Mapping the annual revenues generated by major global players from the influenza diagnostic segment (or the nearest reported business unit/product category)
  • Estimating the revenue of the top ten players to cover at least 65–70% of the global market share, as of 2019
  • Calculating 100% of the global market value of influenza diagnostic based on 65–70% revenue share of the top ten players.

Data Triangulation

After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides of the influenza diagnostics market.

Report Objectives

  • To define, describe, segment, and forecast the influenza diagnostics market on the basis of test type, end user, and region
  • To provide detailed information about the factors influencing market growth, such as drivers, restraints, opportunities, and challenges
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall influenza diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Geographic Analysis

  • Further breakdown of the RoW influenza diagnostics market into Latin America and the Middle East & Africa
  • Further breakdown of the European influenza diagnostics market into Spain and Italy

Company Information

  • Detailed analysis and profiling of additional market players (Up to 5)
Report Code
MD 7514
Published ON
Apr, 2020
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Influenza Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved
...

Digital Virtual Assistant - MarketsandMarkets

Home